Enquyst Technologies

Enquyst Technologies is an innovative private company targeting the multi-billion dollar bioprocess equipment market with its patented Isoelectric Point Purification (IPP) platform. This resin-free, flow-through technology aims to replace multiple chromatography steps in downstream processing, promising significant reductions in cost of goods sold (COGS), increases in yield, and enabling truly continuous manufacturing. Positioned in the Digital Health and AI/ML sectors, Enquyst is pre-revenue and focused on commercializing its platform technology to serve manufacturers of diverse biologics, from monoclonal antibodies to next-generation cell and gene therapies.

Isoelectric Point Purification (IPP) - A patented, resin-free, flow-through purification platform that separates biomolecules using chemistry, physics, and fluid dynamics based on their isoelectric point, charge heterogeneity, and molecular size.

Competes directly with established chromatography giants (Cytiva, Thermo Fisher, Merck KGaA) and their continuous improvement efforts. Also faces competition from other novel purification startups and technologies aiming to reduce downstream costs, such as membrane chromatography, precipitation, and continuous filtration systems.